未知股票 PTIX 深 沪
交易中 05-13 10:26:29 美东时间
0.00
0.000
NaN.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 总市值 0
- 52周最高 --
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 --
- 委 比 0.00%
- 总股本 193.49万
- 历史最高 --
- 量 比 0
- 振 幅 NaN.00%
- 历史最低 --
- 每 手 1
- 风险率 1.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Protagenic Therapeutics Announces Termination of Chief Financial Officer
Protagenic Therapeutics ( ($PTIX) ) has shared an announcement. On March 31, 20...
04-07 18:46
Protagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million
Protagenic Therapeutics Q3 FY2026 operating loss rises 130% to USD 0.93 million on revenue of USD 0.75 million Protagenic reported a loss from operations of USD 0.93 million for Q3 ended Dec. 31, 2025, widening 130% from a year earlier. Legal fees rose to USD 0.22 million, up 565%, and general and a
03-09 19:47
Protagenic Therapeutics Names William Nichols Jr. President
Protagenic Therapeutics Names William Nichols Jr. President Protagenic Therapeutics Inc. appointed William (Bill) Nichols, Jr., 51, as President on February 3, 2026. Nichols previously held senior commercial leadership roles at bluebird bio and earlier at Dova Pharmaceuticals (now Sobi) and Bristol-
03-03 19:06
Protagenic Therapeutics Settles Delaware Chancery Litigation and Unwinds Phytanix Deal
Protagenic Therapeutics Settles Delaware Chancery Litigation and Unwinds Phytanix Deal Protagenic Therapeutics Inc. has entered into a settlement agreement to resolve a Delaware Court of Chancery lawsuit, Protagenic Therapeutics, Inc. v. Alterola Biotech Inc., et al. The settlement provides for dism
02-24 19:04
Protagenic Therapeutics Delays Quarterly 10-Q Filing
Protagenic Therapeutics Delays Quarterly 10-Q Filing Protagenic Therapeutics Inc. filed a Form 12b-25 late-filing notice stating it will not be able to file its quarterly report on Form 10‑Q for the period ended Dec. 31, 2025 by the prescribed due date without unreasonable effort or expense. The com
02-18 19:49
Protagenic Therapeutics Prepares for Nasdaq Delisting, OTC Trading
Protagenic Therapeutics ( ($PTIX) ) just unveiled an announcement. On December ...
01-05 21:18
Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditionsNEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics Inc.
2025-12-09 21:48
Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting
Protagenic Therapeutics Inc. has announced that it will hold its annual meeting of stockholders on December 31, 2025. The meeting will be conducted as a virtual event via live webcast. Disclaimer: Thi...
2025-12-06 05:53
Protagenic Therapeutics receives Nasdaq non-compliance letter
Protagenic Therapeutics (PTIX) has received a notification letter from Nasdaq indicating its non-compliance with the exchange’s listing rules, namely the minimum stockholders' equity requirement and t...
2025-11-27 19:39
Protagenic Therapeutics Faces Nasdaq Delisting Notice
Protagenic Therapeutics ( ($PTIX) ) just unveiled an announcement. On November ...
2025-11-27 05:49
